Subsidised use of methylnaltrexone in Australia for palliative care

Debra S Rowett, Katherine Clark, Maxine K Robinson and David C Currow
Med J Aust 2012; 197 (9): . || doi: 10.5694/mja12.11398
Published online: 5 November 2012

To the Editor: Methylnaltrexone is a peripheral opioid antagonist registered for the treatment of opioid-induced constipation (OIC) on the basis of quality Phase III studies.1 Monitoring uptake of a new medication such as methylnaltrexone after it has been listed on the Pharmaceutical Benefits Scheme (PBS) is crucial to understanding how such medications can be best used in routine clinical practice.

  • Debra S Rowett1
  • Katherine Clark2
  • Maxine K Robinson3
  • David C Currow4

  • 1 Repatriation General Hospital, Adelaide, SA.
  • 2 Calvary Mater Newcastle, Newcastle, NSW.
  • 3 Pharmaceutical Evaluation Branch, Department of Health and Ageing, Canberra, ACT.
  • 4 Flinders University, Adelaide, SA.

Competing interests:

Debra Rowett is a member of the Drug Utilisation Sub-Committee of the Pharmaceutical Benefits Advisory Committee.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.